Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effisayil™ ON: An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Spesolimab Treatment in Patients With Generalized Pustular Psoriasis (GPP)

NCT03886246 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT03886246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03886246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effisayil™ ON: An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Spesolimab Treatment in Patients With Generalized Pustular Psoriasis (GPP)
Lead sponsor
LEO Pharma
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 29, 2019
Completion date
April 27, 2028
Enrollment
131 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

generalized pustular psoriasis